At a startup pitch competition, a local nonprofit won free coworking space for a year to continue their impactful work with individuals with special needs. Photo courtesy of Macy's Miracles

Macy's Miracles, a local nonprofit that helps people with special needs, had a special need of its own: a place to call home. Now, thanks to coworking operator WorkLodge LLC, it has one.

On February 27, representatives of Macy's Miracles and Houston-based WorkLodge held a ribbon-cutting ceremony for the nonprofit's first-ever office. The organization (not affiliated with the Macy's department store chain) won the second annual Shark Tank-inspired Ignite by WorkLodge pitch contest, which awards a one-year WorkLodge lease to a local nonprofit. Macy's Miracle now occupies space at WorkLodge's site in The Woodlands.

Previously, leaders of the nonprofit had carried out business at various public places like coffee shops. Today, the nonprofit enjoys a startup-style setting — including access to meeting rooms and common areas — that enables it to operate more like a business and less like an organization on a shoestring budget.

Haley Ahart-Keiffer, founder and president of Macy's Miracles, says the free one-year lease of a four-person office at WorkLodge (valued at $24,000) is "priceless."

For one thing, being located at WorkLodge opens up fundraising opportunities. In the past, Macy's Miracles ran into roadblocks when prospective corporate sponsors inquired about meeting at the nonprofit's office, Ahart-Keiffer says. But the nonprofit had no formal address to give them.

Now that Macy's Miracles is housed at WorkLodge, folks associated with the nonprofit can more professionally host potential corporate donors and can network with Houston businesses, Ahart-Keiffer says.

As a matter of fact, that networking paid off at the ribbon-cutting ceremony, according to Ahart-Keiffer. For instance, it exposed WorkLodge tenants to potential employees — people attending the ceremony who benefit from services delivered by Macy's Miracles. In addition, the event paved the way for meetings with three businesses interested in assisting Macy's Miracles.

Aside from fostering opportunities for networking, the WorkLodge space lets Macy's Miracles more easily conduct mentorship programs and put on events, according to Ahart-Keiffer.

Being based at WorkLodge "has allowed us to really take it to the next level by being able to seek out even larger corporate sponsors and donors to be a part of the mission," she says.

That mission, carried out since the formation of Macy's Miracles in 2018, centers on elevating the education, networking skills, and employability of people with special needs. Aside from boosting the ability to raise more money for that mission, the WorkLodge space introduces high-functioning people with special needs to a work environment, Ahart-Keiffer says.

In a short amount of time, setting up shop at WorkLodge "has changed the trajectory of where we see that we can go now," she says.

Part of the nonprofit's new trajectory is its soon-to-launch Adaptive Center of Excellence, featuring a vocational/trade initiative and an adaptive sports program.

Ahart-Keiffer didn't envision the current scenario when she established Macy's Miracles two years ago. She established the nonprofit as a "grassroots movement" after her daughter Macy Savoy, who is part of the special needs community, faced a less-than-ideal future in the workforce after graduating from high school. Savoy is CEO of the volunteer-run nonprofit.

Mike Thakur, founder and CEO of WorkLodge, says Ignite by WorkLodge is designed to offer free high-quality space so that nonprofits like Macy's Miracles "take their game up a notch and attract some more support." The contest is geared toward smaller nonprofits making a "hands-on, roll-up-your-sleeves" difference in the community, he says.

In addition to Macy's Miracles securing space at WorkLodge's location in The Woodlands, Ignite by WorkLodge recently granted space to a Dallas nonprofit that's now a tenant at the coworking company's location in the Dallas Design District.

WorkLodge currently operates five coworking spaces: two in the Houston area, two in Dallas-Fort Worth, and one in Tampa-St. Petersburg, Florida.

Thakur says one of the reasons Macy's Miracles received the free space at WorkLodge is that it serves both children and adults.

"But I think the main thing was just the fact that they were delivering help in a way that could then create self-sustainability," says Thakur, whose company runs its own nonprofit foundation. "That's a really big deal for us."

It's also, of course, a big deal for Macy's Miracles. The nonprofit's free one-year lease expires around the end of the year, but Ahart-Keiffer says the Macy's Miracles plans to carve out money in its budget to pay for space at WorkLodge. In conjunction with that, Macy's Miracles will teach some of the members of its mentorship program about fundraising and budgeting.

"I don't think it's a place that we'll ever want to leave," Ahart-Keiffer says. "WorkLodge is definitely the perfect spot for us and what we do."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.